These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30350477)

  • 1. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
    Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
    Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasiglucagon: an effective medicine for severe hypoglycemia.
    Xu B; Tang G; Chen Z
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1783-1790. PubMed ID: 34223944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
    Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R
    Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
    Li S; Hu Y; Tan X; Wang D; Hu J; Zou P; Wang L
    Expert Opin Pharmacother; 2020 Aug; 21(11):1311-1318. PubMed ID: 32267182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetes Care; 2022 Jun; 45(6):1391-1399. PubMed ID: 35475907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
    Pieber TR; Aronson R; Hövelmann U; Willard J; Plum-Mörschel L; Knudsen KM; Bandak B; Tehranchi R
    Diabetes Care; 2021 Jun; 44(6):1361-1367. PubMed ID: 35239971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasiglucagon: First Approval.
    Blair HA
    Drugs; 2021 Jun; 81(9):1115-1120. PubMed ID: 34047955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
    Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
    Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
    Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
    Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetologia; 2023 Jul; 66(7):1208-1217. PubMed ID: 37037948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
    Ju Y; Zhang D; Yang J
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):799-803. PubMed ID: 35848442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.
    Stenninger E; Aman J
    Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.